From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer– insights from the national cancer institute

Abstract Background Triple-negative breast cancer (TNBC) is characterized by its aggressive behavior and limited treatment options, primarily due to the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TROP-2, a transmembr...

Full description

Bibliographic Details
Published in:BMC Cancer
Main Authors: Noura A. A. Ebrahim, Mustafa A. Hussein, Mohamed Emam Sobeih, Nancy H. Amin
Format: Article
Language:English
Published: BMC 2025-06-01
Subjects:
TROP-2
Triple-negative breast cancer
Immunohistochemistry
Precision oncology
Prognostic biomarker
Online Access:https://doi.org/10.1186/s12885-025-14402-7

Internet

https://doi.org/10.1186/s12885-025-14402-7

Similar Items